Tag Archive for: CRO & CDMO

YUMAB multispecific antibodies

New biologic logic – Multispecific antibodies extend targeted therapy beyond one antigen or pathway. By combining binding sites, cell recruitment and defined valencies within one molecule, they enable mechanisms that conventional monoclonal antibodies or their combinations cannot reproduce with the same spatial and pharmacological control.

IDT Biologika

Helping biopharmaceutical innovators build scalable, manufacturable, and commercially viable processes from the start.

eppendorf-new_CDMO115x65V2

For CDMOs, flexible upstream platforms can help streamline process ­development while maintaining reproducibility and continuity across scales.

Justyna Adamczyk, 
Associate VP Integrated MS&T at Rezon Bio

Justyna Adamczyk, Associate VP Integrated MS&T at Rezon Bio, discusses why integrating development and manufacturing strategies is key to improving late-stage efficiency and commercialization readiness.